- |||||||||| A STRANGE CASE OF VIBRIO VULNIFICUS (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1325;
Exposure through open wounds and water contact is not always required. Swift identification and detailed history are crucial for effectively managing Vibrio vulnificus infections.
- |||||||||| levofloxacin / Generic mfg., olanzapine/fluoxetine / Generic mfg.
LEGIONELLA TRIAD: A RARE PRESENTATION OF LEGIONNAIRES' DISEASE (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1173;
This case report highlights a distinct presentation of legionnaires disease associated rhabdomyolysis and acute renal failure and the need to maintain a high degree of suspicion for legionella pneumonia even in patients without classic symptoms like fever, especially for high-risk individuals like those residing in shelters. Our patient was successfully treated with aggressive hydration and appropriate antibiotics and didn't require initiation of hemodialysis, emphasizing the need for early recognition and prompt initiation of treatment.
- |||||||||| quetiapine / Generic mfg.
BRUGADA SYNDROME IN A SCHIZOAFFECTIVE PATIENT: A CASE REPORT (Convention Center Exhibit Hall: Poster Area 1) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1160;
The patient's presentation of schizoaffective disorder and the use of quetiapine were notable aspects of his case... This case report emphasizes the need for awareness and early detection of Brugada Syndrome in patients with schizoaffective disorder to prevent sudden cardiac death.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
A CASE OF SEVERE VOCAL CORD DYSFUNCTION EXACERBATED BY LARYNGOPHARYNGEAL REFLUX (Convention Center Exhibit Hall: Poster Area 1) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1084;
By highlighting this unusual and severe presentation, we hope to encourage physicians to consider VCD as a differential diagnosis in patients presenting with stridor, unresponsive to racemic epinephrine and other non-invasive measures. We also hope to emphasize the importance of considering LPR as possible trigger of VCD and using multimodal approaches for the long-term management of both LPR and VCD.
- |||||||||| olanzapine / Generic mfg., haloperidol / Generic mfg., clozapine / Generic mfg.
Journal: Risk of corrected QT interval prolongation in patients receiving antipsychotics. (Pubmed Central) - Jul 31, 2024
AP use upon hospital admission was linked to early (within 3 days) QTc interval prolongation. Clozapine and olanzapine were associated with a greater increase in QTc interval compared to haloperidol, indicating a need for rigorous electrocardiographic monitoring with their use.
- |||||||||| fluoxetine / Generic mfg.
Review, Journal: The multifaceted effects of fluoxetine treatment on cognitive functions. (Pubmed Central) - Jul 31, 2024
Significantly, the negative cognitive outcomes reported in preclinical research often involve healthy, non-diseased animals. This review underscores the necessity for heightened caution in fluoxetine prescription and further investigation into its potentially detrimental cognitive effects, even when used prophylactically.
- |||||||||| Observational data, Journal: Use and misuse of psychoactive medicines: a descriptive cross-sectional study in a densely populated region of Portugal. (Pubmed Central) - Jul 31, 2024
Chronic use of PMed was observed in 25%, especially with sertraline and buprenorphine for opioid use disorder (long-term treatment), and lorazepam (short-term treatment)...Risk of abuse was low for BZDR, whilst four opioids had meaningful doctor shopping indicators - fentanyl, opioid use disorder buprenorphine, morphine and hydromorphone...Prevalence of OA use is low, although with higher risk of misuse than BZDR. Concomitant use of several PMed is frequent.
- |||||||||| clozapine / Generic mfg.
Retrospective data, Journal: Analysis of clozapine prescribing in the over-65s: 5-year retrospective study. (Pubmed Central) - Jul 31, 2024
Clozapine-induced gastrointestinal hypomotility (CIGH) can be fatal; however, increasing age has not been a recognised risk factor for constipation in clozapine patients to date. This raises questions about increasing risk to physical health as patients age and adds to concerns about the lack of monitoring for CIGH.
- |||||||||| pregabalin / Generic mfg., amitriptyline / Generic mfg., duloxetine / Generic mfg.
Clinical, Observational data, Journal: Amitriptyline, Pregabalin and Duloxetine for Treatment of Painful Diabetic Peripheral Neuropathy. (Pubmed Central) - Jul 31, 2024
This raises questions about increasing risk to physical health as patients age and adds to concerns about the lack of monitoring for CIGH. Amitriptyline, pregabalin and duloxetine were all associated with adequate pain reduction among patients of painful diabetic peripheral neuropathy in our study, however, amitriptyline had more favorable findings with tolerable side effects.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial primary completion date: The Efficacy of Botulinum Toxin Vs. Corticosteroid for the Treatment of Refractory Plantar Fasciitis (clinicaltrials.gov) - Jul 31, 2024
P2/3, N=62, Active, not recruiting,
Amitriptyline, pregabalin and duloxetine were all associated with adequate pain reduction among patients of painful diabetic peripheral neuropathy in our study, however, amitriptyline had more favorable findings with tolerable side effects. Trial primary completion date: Apr 2024 --> Sep 2024
- |||||||||| tramadol hydrochloride / Generic mfg.
Tramadol for Pain Management Associated with Serotonin Syndrome (Exhibit Hall) - Jul 31, 2024 - Abstract #PAINWeek2024PAINWeek_241;
This recommendation was made based on multiple areas of concern. First, drug-drug interactions between tramadol, sertraline, and quetiapine were noted to increase serotonin in the central nervous system and therefore increase the risk of serotonin syndrome.
- |||||||||| amitriptyline / Generic mfg., topiramate / Generic mfg.
Journal: Successful treatment with traditional Japanese medicine (kampo medicine) Yokukansan as a migraine prophylactic drug: A case report. (Pubmed Central) - Jul 30, 2024
We speculate that, in this case, migraine without aura was improved by prophylactic therapy with yokukansan due to its action on the glutamatergic system or serotonin system through suppression of orexin-A secretion or its anti-inflammatory effects as reported in previous animal studies. Yokukansan could be a usable kampo medicine for migraine prophylaxis in countries all over the world and should be investigated in a large clinical trial as soon as possible.
- |||||||||| aripiprazole / Generic mfg., cabergoline / Generic mfg.
Review, Journal: Cardiometabolic effects of hypoprolactinemia. (Pubmed Central) - Jul 30, 2024
This evidence has been collected mainly in patients on chronic treatment with dopamine agonists for PRL excess due to a PRL-secreting pituitary tumour, and less frequently in those receiving the atypical antipsychotic aripiprazole...Nevertheless, current knowledge still lacks an accurate biochemical definition of hypoprolactinemia, since no clear PRL threshold has been established to rule in the diagnosis of PRL deficiency enabling early identification of those individual subjects with increased cardiovascular risk directly ascribable to the hormonal imbalance. The current review article focuses on the effects of hypoprolactinemia on the modulation of body weight, gluco-insulinemic and lipid profile, and provides latest knowledge about potential cardiovascular outcomes of hypoprolactinemia.
- |||||||||| carbamazepine / Generic mfg., haloperidol / Generic mfg.
Journal: Case 327: Exogenous Lipoid Pneumonia. (Pubmed Central) - Jul 30, 2024
Noninvasive ventilation was initiated. Imaging performed during the second ICU hospitalization included CT and MRI of the chest without contrast enhancement, and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Journal: LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up. (Pubmed Central) - Jul 30, 2024
Imaging performed during the second ICU hospitalization included CT and MRI of the chest without contrast enhancement, and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT. Patients reported sustained long-term effects of LSD-assisted therapy for anxiety.
- |||||||||| escitalopram / Generic mfg.
Journal: The Emergence of Mania After Initiating Escitalopram for Anxiety Disorder. (Pubmed Central) - Jul 30, 2024
The patient was in the acute inpatient psychiatric unit for 25 days and returned to baseline after discontinuation of escitalopram and initiating divalproex and olanzapine. This case underscores the potential risk of a bipolar switch with antidepressant use and highlights the importance of vigilant monitoring and considering underlying bipolarity in such patients.
- |||||||||| fluvoxamine / Generic mfg., omeprazole / Generic mfg., voriconazole / Generic mfg.
Journal: Phenoconversion Due to Drug-Drug Interactions in CYP2C19 Genotyped Healthy Volunteers. (Pubmed Central) - Jul 30, 2024
Statistically significant differences were observed in mean metabolic ratios between CYP2C19 intermediate metabolizers (g-IMs) with *1/*2 and *2/*17 genotypes, with the *2/*17 group exhibiting lower ratios, and distinctions were noted between genotypic groups, emphasizing the impact of genetic variations on drug metabolism. When reclassified according to CYP2C19 baseline-measured phenotype into p-RM, p-NM, and p-IM (p- for measured phenotype), we observed 100% phenoconversion of p-RMs and a significant phenotype switch in p-NMs, p-IMs, and p-PMs after fluvoxamine and voriconazole, and complete phenoconversion of p-IMs to p-PMs on both inhibitors, emphasizing the impact of genetic variations on the vulnerability to CYP2C19 phenoconversion and the importance of considering both genotyping and phenotyping in predicting drug response.
- |||||||||| duloxetine / Generic mfg.
Journal, Adverse events: Daytime bruxism, tardive orofacial dyskinesia, and dysphagia as side effects to duloxetine use over nine years in an octogenarian. (Pubmed Central) - Jul 30, 2024
When reclassified according to CYP2C19 baseline-measured phenotype into p-RM, p-NM, and p-IM (p- for measured phenotype), we observed 100% phenoconversion of p-RMs and a significant phenotype switch in p-NMs, p-IMs, and p-PMs after fluvoxamine and voriconazole, and complete phenoconversion of p-IMs to p-PMs on both inhibitors, emphasizing the impact of genetic variations on the vulnerability to CYP2C19 phenoconversion and the importance of considering both genotyping and phenotyping in predicting drug response. No abstract available
- |||||||||| clozapine / Generic mfg.
Journal: Severe neutropenia unrelated to clozapine in patients receiving clozapine. (Pubmed Central) - Jul 30, 2024
The widely used threshold criterion-based diagnosis overestimates the risk of agranulocytosis. True clozapine-related agranulocytosis is best identified by pattern-based criteria: rapid fall in neutrophil counts over around 2 weeks to below 0.5
- |||||||||| levetiracetam / Generic mfg., memantine / Generic mfg.
Review, Journal: Alzheimer's disease and epilepsy: Research hotspots for comorbidity in the era of global aging. (Pubmed Central) - Jul 29, 2024
Animal models are recognized for their importance in understanding the relationship between AD and epilepsy, though creating fully representative models presents a challenge. The review concludes by noting the efficacy of medications such as lamotrigine, levetiracetam, and memantine in managing both conditions and suggests the ketogenic diet and cannabidiol as emerging treatment options, warranting further investigation for comprehensive patient care strategies.
- |||||||||| risperidone / Generic mfg.
Journal: A hybrid model for predicting response to risperidone after first episode of psychosis. (Pubmed Central) - Jul 29, 2024
The hybrid model, which included duration of untreated psychosis, Clinical Global Impression-Severity scale scores, age, cannabis use, and 406 SNVs, showed the best performance (balanced accuracy: 72.9% [CI 0.62-0.84] - RF algorithm). A hybrid model, including clinical and genetic predictors, can provide enhanced predictions of response to antipsychotic treatment.
- |||||||||| Clinical, Journal: Comparison Table: Some oral antiseizure medications. (Pubmed Central) - Jul 29, 2024
A hybrid model, including clinical and genetic predictors, can provide enhanced predictions of response to antipsychotic treatment. No abstract available
- |||||||||| Review, Journal: Drugs for epilepsy. (Pubmed Central) - Jul 29, 2024
No abstract available No abstract available
- |||||||||| olanzapine / Generic mfg.
Journal: The crystal structure of olanzapine form III. (Pubmed Central) - Jul 29, 2024
Olanzapine form III is monoclinic and shows a similar but shifted packing with respect to form II. It is remarkably different from the lowest-energy structures predicted by the energy-minimization algorithms of crystal structure prediction.
- |||||||||| Review, Journal: Antidepressants in psychiatric practice (Pubmed Central) - Jul 29, 2024
This fact increases confidence in these medicines. Some features of the use of these antidepressants based on clinical recommendations and personal experience are discussed in the article.
- |||||||||| fluvoxamine / Generic mfg.
Review, Journal: Fluvoxamine in the treatment of anxiety-depressive spectrum disorders (Pubmed Central) - Jul 29, 2024
The data of the above studies indicate that fluvoxamine (Zovart San) in doses of 50-300 mg / day is a highly effective remedy for the treatment of not only anxiety depressions and genesis (psychogenic, organic, mixed, autochthonous-endogenous) and severity (up to psychotic), but also a wider range of anxiety-depressive disorders, including adaptation disorders, obsessive-compulsive disorder, somatized, dysmorphic, insomniac symptom complexes and eating disorders. A wide range of clinical effects of fluvoxamine is due to its main and additional mechanisms of action: blockade of serotonin reuptake, ?1-agonist activity and the effect on the metabolism of melatonin and neurosteroids catabolism.
- |||||||||| paclitaxel / Generic mfg., duloxetine / Generic mfg.
Preclinical, Journal: An investigation on the role of oxytocin in chronic neuropathic pain in a Wistar rat model. (Pubmed Central) - Jul 29, 2024
Conclusion Our results support the hypothesis that intranasally administered oxytocin may augment the analgesic and anxiolytic effects of duloxetine in a chemotherapy induced peripheral neuropathy model in a Wistar rat. Future studies should consider administering the treatments in combination to observe the potential synergistic effects.
- |||||||||| Resolor (prucalopride) / J&J, Takeda
Journal: Induction of long-term hyperexcitability by memory-related cAMP signaling in isolated nociceptor cell bodies. (Pubmed Central) - Jul 29, 2024
Six-hour treatment with the specific G?s-coupled 5-HT4 receptor agonist, prucalopride, or with the adenylyl cyclase activator, forskolin, induced long-term hyperexcitability (LTH) in DRG neurons that manifested 12-24 hours later as action potential (AP) discharge (ongoing activity, OA) during artificial depolarization to -45 mV, a membrane potential that is normally subthreshold for AP generation...An interesting possibility is that these mechanisms can also be reactivated by re-exposure to inflammatory mediators such as serotonin during subsequent challenges to bodily integrity, "reconsolidating" the cellular memory and thereby extending the duration of persistent nociceptor hyperexcitability. Nociceptor long-term hyperexcitability (LTH) can be induced by a 5-HT4R agonist.5-HT4R-induced LTH manifests as ongoing activity during modest depolarization.Enhanced ongoing activity is associated with long-term potentiation of DSFs.Induction of LTH depends upon PKA, CREB, transcription, and protein synthesis.Nociceptor LTH may be triggered by conserved memory-related plasticity mechanisms.
- |||||||||| Caplyta (lumateperone) - Intra / Cellular Therapies
Journal: Treatment of a resistant case of schizoaffective disorder with lumateperone: A case report. (Pubmed Central) - Jul 29, 2024
Interestingly, it has a similar structure and mechanism of action to paliperidone, the only Food and Drug Administration-approved medication for schizoaffective disorder. Through this case report, as an example of lumateperone's effectiveness and tolerability, as well as a literature review of its pharmacodynamics, we make the case that lumateperone emerges as a promising option for schizoaffective disorder, especially treatment-resistant cases.
- |||||||||| asenapine / Generic mfg.
Journal: Sublingual asenapine for agitation in malabsorptive states: three patient cases. (Pubmed Central) - Jul 29, 2024
Clinicians should consider the use of SL asenapine for medically complex agitated patients where gastric absorption is questionable. There is an urgent need for guidelines on this matter, as well as more, alternative dosage forms for various medications that may help with agitation in this population.
- |||||||||| Review, Journal: Effects of selective serotonin reuptake inhibitors on endocrine system (Review). (Pubmed Central) - Jul 29, 2024
According to the available literature, SSRIs may have an adverse effect on glucose metabolism, sexual function and fertility by dysregulating the function of the HPA axis, pancreas and gonads. Therefore, considering that SSRIs are often prescribed for extended periods, it is crucial to monitor the patient closely with particular attention to the function of the endocrine system.
|
